NOV 24, 2015 12:08 PM PST

Brain Inflammation Linked to Persistant Depression Symptoms

WRITTEN BY: Kara Marker
A large number of people diagnosed with depression experience an inability to feel pleasure, and antidepressants don't seem to be helping. A new study from Emory Health Sciences has shown that inflammation in the brain is causing the disconnect, and anti-inflammatory drugs could reverse the effect.

"Anhedonia," also know as the loss in interest of previously pleasing activities like talking with friends, being outside or listening to music, is a common symptom of people with major depressive disorder (Psychology Today). Newly linked to inflammation, prior to this discovery doctors were unsure why antidepressants did not solve this problem associated with depression. 

In a study published this month in Molecular Psychiatry, scientists from Emory looked at brain images of 48 patients diagnosed with depression to investigate the potential of this "inflammatory depression." They analyzed the levels of c-reactive protein (CRP), an inflammatory marker produced by the liver in response to inflammation in the body (MedlinePlus). They collected brain images of their participants while they were not on any antidepressants or other drugs and compared the images to their CRP levels.
C-reactive protein

A clear connection was made between patients experiencing and reporting anhedonia and high levels of CRP circulating in their blood. In addition, brain images from these patients showed "low functional connectivity" between two regions of the brain related to motivation and reward. Patients with low levels of CRP did not report experiencing anhedonia and had normal connectivity between these brain regions.

"We were interested in these regions of the brain because of their known importance for response to reward," said lead author Jennifer Felger, PhD, assistant professor of psychiatry and behavioral sciences at Emory University School of Medicine and Winship Cancer Institute.

Scientists were also prompted to make this connection since decreased activity of the same two brain regions was seen in hepatitis C patients receiving "immuno-stimulatory" treatments that boosted inflammation. Scientists have begun using anti-inflammatory treatments for anhedonia patients and seen improvement. No change was seen in patients without anhedonia when given the same treatment. 

The next step, being pursued by the same group from Emory, is to test the effectiveness of L-DOPA therapy on anhedonia patients. L-DOPA therapy is currently used to treat Parkinson's disease by acting as a neurotransmitter and stimulating brain activity. 

Watch the following video to learn more about L-DOPA and how it works.

Source: Emory Woodruff Health Sciences Center
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 29, 2018
Immunology
OCT 29, 2018
Immunity for All
A study published in Nature has shed light on the evolution of immune system genes across species with great detail at the single-cell level...
NOV 25, 2018
Health & Medicine
NOV 25, 2018
Why Does E. Coli Make us Sick?
  Escherichia coli, or E. coli refer to a diverse group of of bacteria commonly found in the lower intestine of warm blooded animals. While E. coli ga...
NOV 28, 2018
Immunology
NOV 28, 2018
Regulators to the Rescue
Scientists at Scripps Research Institute describe the nature of an immune regulator protein...
DEC 18, 2018
Cancer
DEC 18, 2018
A new spray that can stop skin cancer recurrence and metastasis
Cancer recurrence and metastasis are the leading causes of death in cancer patients; this is why researchers at UCLA developed something that could help in stopping recurrence or metastasis i...
JAN 15, 2019
Immunology
JAN 15, 2019
A Possible Key to Severe Flu
By studying the impact that NPY and its receptor Y1R have on influenza in mice, the research group has now discovered that NPY produced in lung phagocytes can aggravate influenza....
Loading Comments...